Quick Answer
Tirzepatide is a dual agonist of GIP and GLP-1 receptors. Retatrutide is an investigational triple agonist of GIP, GLP-1, and glucagon receptors.
That extra glucagon receptor activity is the main scientific difference. Tirzepatide is approved for certain uses and has a large real-world footprint. Retatrutide is still in development, but its reported weight-loss results have made it one of the most watched next-generation compounds.
Explore the AminoRank retatrutide profileReview linked studies, category details, and vendor availability for retatrutide.View retatrutide profileMechanism Comparison
Tirzepatide changed the incretin conversation by combining GIP and GLP-1 activity. Retatrutide builds on that idea by adding glucagon receptor activity.
| Compound | Mechanism |
|---|---|
| Tirzepatide | GIP and GLP-1 receptor agonist. |
| Retatrutide | GIP, GLP-1, and glucagon receptor agonist. |
The glucagon pathway is the key difference. It may contribute to energy-metabolism effects, which is one reason retatrutide's weight-loss results have drawn so much attention.
That makes this comparison more interesting than "old drug versus new drug." Tirzepatide showed what dual agonism could do. Retatrutide is testing whether adding glucagon receptor activity creates a meaningfully stronger metabolic profile.
Approval And Evidence Status
Tirzepatide is approved under different brands for type 2 diabetes and chronic weight management. That gives it a mature prescribing and post-approval context.
Retatrutide is not approved. It has published Phase 2 obesity data and reported Phase 3 updates, but it remains an investigational compound.
This is the cleanest way to compare them: tirzepatide is established, while retatrutide is the high-interest next-generation candidate.
Weight-Loss Results
In SURMOUNT-1, tirzepatide produced large weight reductions over 72 weeks, with the highest dose group losing around 20.9% on average. The FDA's Zepbound approval summary also describes substantial weight loss in chronic weight management trials.
Retatrutide's Phase 2 obesity trial reported up to 24.2% mean weight loss at 48 weeks, and TRIUMPH-4 later reported 28.7% mean weight loss at 68 weeks in adults with obesity or overweight and knee osteoarthritis.
Those numbers are why the comparison is so popular. The careful interpretation is that retatrutide has reported extremely strong results, but the compounds have not been reduced to a simple interchangeable ranking.
The cleaner comparison is evidence maturity versus upside. Tirzepatide has approvals, labeling, and a large base of use. Retatrutide has the more dramatic investigational weight-loss signal, but it still needs the full Phase 3 and regulatory story to mature.
Dosing Chart Caveat
Retatrutide vs tirzepatide dosage charts are risky because they imply conversion where none is established. Tirzepatide has approved dosing. Retatrutide has clinical-trial dosing.
The mechanisms are different, the regulatory status is different, and the evidence base is different. A chart can compare study doses, but it should not tell a person how to switch or convert.
For trial context, see retatrutide dosing.
Side Effects
Both compounds are associated with gastrointestinal side effects in the broader incretin category. Nausea, diarrhea, vomiting, constipation, and appetite-related effects are common discussion points.
Retatrutide's full safety profile will become clearer as more Phase 3 publications and long-term data become public.
Research Vendor Context
Retatrutide appears in research-vendor listings, while tirzepatide has approved commercial products and also appears in research contexts. For retatrutide, the useful vendor signals are COAs, reviews, promo codes, payment options, shipping, and country.
Compare retatrutide research vendorsBrowse vendors by COAs, reviews, discounts, shipping, and payment options.View retatrutide vendorsFor buyer-intent readers, that distinction matters. A tirzepatide comparison may lead to approved-product questions. A retatrutide comparison should still be framed around research availability, documentation, and clinical development status.
Bottom Line
Tirzepatide is the proven dual agonist. Retatrutide is the investigational triple agonist with standout reported results. The comparison is useful because it shows where metabolic drug development is going, but it should not be used as a personal conversion guide.
For the semaglutide comparison, see retatrutide vs semaglutide.
FAQ
Is retatrutide stronger than tirzepatide?
Retatrutide has reported very strong results, but direct superiority claims require careful trial context or head-to-head evidence.
Is tirzepatide dual agonist or triple agonist?
Tirzepatide is a dual GIP and GLP-1 receptor agonist.
Is retatrutide triple agonist?
Yes. Retatrutide activates GIP, GLP-1, and glucagon receptors.
Can I use a retatrutide vs tirzepatide dosage chart?
Charts can compare study doses, but they should not be used for personal conversion or switching advice.